Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | Multiple Myeloma | Research article

Oral cryotherapy for management of chemotherapy‐induced oral mucositis in haematopoietic cell transplantation: a systematic review

Authors: Faizah Jabr Alsulami, Sadr ul Shaheed

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

Oral mucositis (OM) is known to be the most common and challenging side effect of conditioning chemotherapy in haematopoietic cell transplant (HCT). This side effect causes significant morbidity and may delay the treatment plan, as well as increase therapeutic expenses. There are few clinical trials in the literature that indicate any kind of treatment or prevention methods are effective. Therefore, the aim of this study is to perform a systematic review of literature and examine the effectiveness of oral cryotherapy (OC) in management of chemotherapy-induced OM in patients with haematological malignancies undergoing a HCT.

Methods

A systematic literature search was conducted, using the electronic databases PubMed, Embase, MEDLINE and Scopus. A total of 322 papers were identified and 9 papers were analysed based on defined inclusion and exclusion criteria. The quality of the chosen primary studies was appraised using the COCHRANE risk of bias assessment tool.

Results

Nine randomized controlled trials, analysing 658 participants; control group (n = 289, age mean ± SD; 41.15 ± 21) and treatment group (n = 369, age mean ± SD; 39.15 ± 20), were included in this systematic review. Seven studies had significantly addressed the effectiveness of OC (p value < 0.05), in reducing the incidence of developing severe OM in the adult population undergoing HCT, especially when the conditioning regimen protocols included high dose of alkylating agent such as melphalan.

Conclusion

This review supports the use of OC for prevention of OM in patients undergoing HCT, with high-dose of melphalan conditioning protocols. It is recommended that more studies be conducted to compare efficacy and duration of OC with other chemotherapeutic agents with relatively short plasma half-lives. The heterogeneity of the trials demonstrated the need to regulate the validated assessment tools and similar interventions that would enable comparisons and analyses of treatment effects based on well-designed RCTs.
Literature
1.
Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol. 2011;4(4):437–52.PubMedPubMedCentralCrossRef
2.
3.
Passweg JR, Baldomero H, Chabannon C, Basak GW, De La Camara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56(7):1651–64.PubMedPubMedCentralCrossRef
4.
Nishimura KK, Barlogie B, van Rhee F, Zangari M, Walker BA, Rosenthal A, et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 2020;4(2):422–31.PubMedPubMedCentralCrossRef
5.
BeTheMatch/NationalMarrowDonorProgram(NMDP). International Marrow Donor Registries Reach 25 Million Potential Donors, Give Hope to Searching Blood Cancer Patients Around the World. 2015. (col. 2020).
6.
Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood J Am Soc Hematol. 2014;124(3):344–53.
7.
Atilla E, Atilla PA, Demirer T. A review of myeloablative vs reduced intensity/non-myeloablative regimens in allogeneic hematopoietic stem cell transplantations. Balkan Med J. 2017;34(1):1–9.PubMedPubMedCentralCrossRef
8.
Katranci N, Ovayolu N, Ovayolu O, Sevinc A. Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial. Eur J Oncol Nurs. 2012;16(4):339–44.PubMedCrossRef
9.
Peterson DE, Ohrn K, Bowen J, Fliedner M, Lees J, Loprinzi C, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013;21(1):327–32.PubMedCrossRef
10.
11.
Riley P, McCabe MG, Glenny AM. Oral Cryotherapy for Preventing Oral Mucositis in Patients Receiving Cancer Treatment. JAMA Oncol. 2016;2(10):1365–6.PubMedCrossRef
12.
Biagioli V, Piredda M, Mauroni MR, Alvaro R, De Marinis MG. The lived experience of patients in protective isolation during their hospital stay for allogeneic haematopoietic stem cell transplantation. Eur J Oncol Nurs. 2016;24:79–86.PubMedCrossRef
13.
Alvarino-Martin C, Sarrion-Perez MG. Prevention and treatment of oral mucositis in patients receiving chemotherapy. J Clin Exp Dent. 2014;6(1):74–80.CrossRef
14.
Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy-and radiotherapy-induced mucositis. Ann Oncol. 2007;18(5):817–26.PubMedCrossRef
15.
Roldan CJ, Chung M, Feng L, Bruera E. Methylene blue for the treatment of intractable pain from oral mucositis related to cancer treatment: an uncontrolled cohort. J Natl Compr Canc Netw. 2021;19(5):521–7.PubMedCrossRef
16.
Elsabagh HH, Moussa E, Mahmoud SA, Elsaka RO, Abdelrahman H. Efficacy of Melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial. Oral Dis. 2020;26(3):566–72.PubMedCrossRef
17.
Sharifi H, Heydari A, Salek R, Emami ZA. Oral cryotherapy for preventing chemotherapy-induced oral mucositis: An effective but yet neglected strategy. J Cancer Res Ther. 2017;13(2):386–7.PubMedCrossRef
18.
Park S-H, Han SH. Effect of oral cryotherapy for reducing oral mucositis in hematopoietic stem cell transplantation: a systematic review and meta-analysis. Korean J Adult Nurs. 2018;30(4):362–75.CrossRef
19.
Svanberg A, Öhrn K, Broström H, Birgegård G. The effect of cryotherapy on oral mucosa: a study in healthy volunteers. Med Oncol. 2012;29(5):3587–91.PubMedCrossRef
20.
Wang L, Gu Z, Zhai R, Zhao S, Luo L, Li D, et al. Efficacy of oral cryotherapy on oral mucositis prevention in patients with hematological malignancies undergoing hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. PLoS One. 2015;10(5):e0128763.PubMedPubMedCentralCrossRef
21.
22.
Riley P, Glenny AM, Worthington HV, Littlewood A, Clarkson JE, McCabe MG. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev. 2015;2015(12):CD011552.PubMedCentral
23.
Correa MEP, Cheng KKF, Chiang K, Kandwal A, Loprinzi CL, Mori T, et al. Systematic review of oral cryotherapy for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2020;28(5):2449–56.PubMedCrossRef
24.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedPubMedCentralCrossRef
25.
Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37(11):1031–5.PubMedCrossRef
26.
Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy–a randomized controlled trial. Support Care Cancer. 2007;15(10):1155–61.PubMedCrossRef
27.
Svanberg A, Ohrn K, Birgegard G. Oral cryotherapy reduces mucositis and improves nutrition - a randomised controlled trial. J Clin Nurs. 2010;19(15–16):2146–51.PubMedCrossRef
28.
Salvador P, Azusano C, Wang L, Howell D. A pilot randomized controlled trial of an oral care intervention to reduce mucositis severity in stem cell transplant patients. J Pain Symptom Manage. 2012;44(1):64–73.PubMedCrossRef
29.
Askarifar M, Lakdizaji S, Ramzi M, Rahmani A, Jabbarzadeh F. The Effects of Oral Cryotherapy on Chemotherapy-Induced Oral Mucositis in Patients Undergoing Autologous Transplantation of Blood Stem Cells: A Clinical Trial. Iran Red Crescent Med J. 2016;18(4):e24775.PubMedPubMedCentralCrossRef
30.
Marchesi F, Tendas A, Giannarelli D, Viggiani C, Gumenyuk S, Renzi D, et al. Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplant. 2016;52(1):154–6.PubMedCrossRef
31.
Lu Y, Zhu X, Ma Q, Wang J, Jiang P, Teng S, et al. Oral cryotherapy for oral mucositis management in patients receiving allogeneic hematopoietic stem cell transplantation: a prospective randomized study. Support Care Cancer. 2020;28(4):1747–54.PubMedCrossRef
32.
Kamsvag T, Svanberg A, Legert KG, Arvidson J, von Essen L, Mellgren K, et al. Prevention of oral mucositis with cryotherapy in children undergoing hematopoietic stem cell transplantations-a feasibility study and randomized controlled trial. Support Care Cancer. 2020;28(10):4869–79.PubMedPubMedCentralCrossRef
33.
Gori E, Arpinati M, Bonifazi F, Errico A, Mega A, Alberani F, et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. Bone Marrow Transplant. 2007;39(6):347–52.PubMedCrossRef
34.
Bast Jr RC, Croce CM, Hait WN, Hong WK, Kufe DW, Piccart-Gebart M, et al. Holland-Frei Cancer Medicine Cloth: John Wiley & Sons; 2017.
35.
WHO. WHO handbook for reporting results of cancer treatment: World Health Organization. 1979.
36.
Mori T, Yamazaki R, Aisa Y, Nakazato T, Kudo M, Yashima T, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2006;14(4):392–5.PubMedCrossRef
37.
Migliorati CA, Oberle-Edwards L, Schubert M. The role of alternative and natural agents, cryotherapy, and/or laser for management of alimentary mucositis. Support Care Cancer. 2006;14(6):533–40.PubMedCrossRef
38.
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100(S9):1995–2025.PubMedCrossRef
39.
Bjordal JM, Bensadoun R-J, Tunèr J, Frigo L, Gjerde K, Lopes-Martins RA. A systematic review with meta-analysis of the effect of low-level laser therapy (LLLT) in cancer therapy-induced oral mucositis. Support Care Cancer. 2011;19(8):1069–77.PubMedCrossRef
40.
Blijlevens N, Schwenkglenks M, Bacon P, D’Addio A, Einsele H, Maertens J, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy—European Blood and Marrow Transplantation Mucositis Advisory Group. J CLIN ONCOL. 2008;26(9):1519–25.PubMedCrossRef
41.
Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A, et al. Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin’s lymphoma: A monocenter prospective study. Am J Hematol. 2007;82(2):122–7.PubMedCrossRef
42.
Fadda G, Campus G, Lugliè P. Risk factors for oral mucositis in paediatric oncology patients receiving alkylant chemotherapy. BMC Oral Health. 2006;6(1):1–8.CrossRef
43.
Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13(7):1786–99.PubMedCrossRef
44.
Zimmermann-Franco DC, Esteves B, Lacerda LM, de Oliveira Souza I, Dos Santos JA, Pinto NdCC, et al. In vitro and in vivo anti-inflammatory properties of imine resveratrol analogues. Bioorg Med Chem. 2018;26(17):4898–906.PubMedCrossRef
45.
Keefe D, Schubert M, Elting L, Sonis S, Epstein J, Raber-Durlacher J, et al. Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109(5):820–31.PubMedCrossRef
46.
Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A, et al. 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. Oncotarget. 2018;9(14):11559.PubMedPubMedCentralCrossRef
47.
Aisa Y, Mori T, Kudo M, Yashima T, Kondo S, Yokoyama A, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. Support Care Cancer. 2005;13(4):266–9.PubMedCrossRef
48.
Johansson J-E, Bratel J, Hardling M, Heikki L, Mellqvist U-H, Hasséus B. Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial. Bone Marrow Transplant. 2019;54(9):1482–8.PubMedCrossRef
49.
Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate-and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005;11(5):383–8.PubMedCrossRef
50.
Schmidt V, Niederwieser D, Schenk T, Behre G, Klink A, Pfrepper C, et al. Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53(9):1188–92.PubMedCrossRef
Metadata
Title
Oral cryotherapy for management of chemotherapy‐induced oral mucositis in haematopoietic cell transplantation: a systematic review
Authors
Faizah Jabr Alsulami
Sadr ul Shaheed
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-09539-8

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue

Research

Preoperative prediction of intrahepatic cholangiocarcinoma lymph node metastasis by means of machine learning: a multicenter study in China

Research

Promoter methylation of transient receptor potential melastatin-related 7 (TRPM7) predicts a better prognosis in patients with Luminal A breast cancers

Research

M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma

Research

Prescreening of tumor samples for tumor-centric transcriptome analyses of lung adenocarcinoma

Study protocol

Oncologic outcomes of single-incision laparoscopic surgery versus conventional laparoscopic surgery for colorectal cancer (CSILS): study protocol for a multicentre, prospective, open-label, noninferiority, randomized controlled trial

Research

Serum untargeted lipidomics by UHPLC-ESI-HRMS aids the biomarker discovery of colorectal adenoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits